Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 8/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274983 | 0.91 | ALDH1A1 (0.43) | NPSR1SIGMAR1DRD3ALDH1A1TDP1 | |
| SCHEMBL3278108 | 0.90 | GSK3B (0.44) | CYP1A2CYP3A4CYP2D6GSK3BCNR2 | |
| SCHEMBL3274941 | 0.84 | GSK3B (0.51) | CYP1A2CYP2D6GSK3B | |
| SCHEMBL3280340 | 0.84 | GSK3B (0.42) | LMNACYP1A2CYP2D6GSK3BCNR2 | |
| SCHEMBL3274308 | 0.84 | HTR4 (0.48) | DRD3LMNAALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL3274906 | 0.82 | GSK3B (0.42) | CYP1A2CYP3A4CYP2D6GSK3BCNR2 | |
| SCHEMBL3274046 | 0.82 | NPC1 (0.49) | CYP1A2CYP2D6GSK3BCNR2 | |
| SCHEMBL3273623 | 0.81 | GSK3B (0.45) | CYP1A2CYP3A4CYP2D6GSK3B | |
| SCHEMBL3277958 | 0.81 | MAPT (0.47) | LMNAALDH1A1GSK3BHPGD | |
| SCHEMBL3273383 | 0.80 | GSK3B (0.41) | NPSR1ALDH1A1TDP1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160388-B1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2013-12-18 | — | — | EP | claimed |
| US-8598187-B2 | Arylamide pyrimidone compounds | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | claimed |
| EP-2160388-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | claimed |
| WO-2008155670-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | claimed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| EP-1992625-A1 | Arylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| EP-2160388-B1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-8598187-B2 | Arylamide pyrimidone compounds | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2160388-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008155670-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992625-A1 | Arylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | DHFR, HPRT1, XDH | NPSR1 245/4885SIGMAR1 932/4885DRD3 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.